Andra AP fonden reduced its stake in shares of CVS Health Corporation (NYSE:CVS – Free Report) by 76.2% during the 1st quarter, HoldingsChannel reports. The fund owned 89,487 shares of the pharmacy operator’s stock after selling 285,913 shares during the period. Andra AP fonden’s holdings in CVS Health were worth $6,427,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of the stock. Swiss RE Ltd. acquired a new stake in CVS Health during the fourth quarter valued at $26,000. Sankala Group LLC acquired a new position in CVS Health in the 4th quarter worth about $28,000. Caitong International Asset Management Co. Ltd increased its position in CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 281 shares during the last quarter. Mcguire Capital Advisors Inc. purchased a new stake in shares of CVS Health during the 4th quarter worth about $28,000. Finally, Ares Financial Consulting LLC acquired a new stake in shares of CVS Health during the 4th quarter valued at about $29,000. 80.66% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
CVS has been the topic of several recent research reports. Weiss Ratings raised shares of CVS Health from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday. Wells Fargo & Company raised their price target on shares of CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Morgan Stanley lifted their price objective on shares of CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a research note on Thursday, June 4th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of CVS Health from $88.00 to $92.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, Cantor Fitzgerald raised their target price on CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. Twenty-one research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and a consensus price target of $105.38.
CVS Health Price Performance
Shares of NYSE:CVS opened at $107.96 on Thursday. The business has a 50 day moving average price of $99.78 and a 200 day moving average price of $85.78. CVS Health Corporation has a twelve month low of $58.50 and a twelve month high of $110.68. The company has a market cap of $137.75 billion, a price-to-earnings ratio of 47.56, a PEG ratio of 1.08 and a beta of 0.61. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78.
CVS Health (NYSE:CVS – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. During the same period in the previous year, the business posted $2.25 EPS. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Research analysts predict that CVS Health Corporation will post 7.46 earnings per share for the current year.
CVS Health Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 23rd will be paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 2.5%. The ex-dividend date is Thursday, July 23rd. CVS Health’s dividend payout ratio is presently 117.18%.
Insiders Place Their Bets
In other news, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the transaction, the director owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. The trade was a 87.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 3,441,551 shares of company stock valued at $323,703,977. Insiders own 0.85% of the company’s stock.
Key CVS Health News
Here are the key news stories impacting CVS Health this week:
- Positive Sentiment: CVS is expanding its pharmacy offering to include select pet prescriptions nationwide, a move that could drive incremental foot traffic and sales. Pet medications now available at CVS Pharmacy®
- Positive Sentiment: Analysts and market commentary noted improving execution and a better payer margin outlook, which can reinforce confidence in CVS’s earnings trajectory. CVS Health Corporation (CVS) Rose on Improving Execution and Payer Margin Outlook
- Neutral Sentiment: CVS also highlighted ongoing community health investments in Massachusetts, underscoring its broader social and healthcare footprint, though the immediate stock impact appears limited. CVS Health Helping to Strengthen Communities Across Massachusetts
- Negative Sentiment: Henry Ford Health’s lawsuit alleging a 340B pricing scheme creates legal and reimbursement uncertainty, which could pressure sentiment around CVS’s pharmacy operations. Henry Ford Health sues CVS over alleged $29 million pricing scheme
About CVS Health
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
See Also
- Five stocks we like better than CVS Health
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS – Free Report).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.
